Advertisement

Journal of Neuro-Oncology

, Volume 77, Issue 2, pp 131–140 | Cite as

Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival

  • Järvelä Sally
  • Bragge Helena
  • Paunu Niina
  • Järvelä Timo
  • Paljärvi Leo
  • Kalimo Hannu
  • Helén Pauli
  • Kinnula Vuokko
  • Soini Ylermi
  • Haapasalo Hannu
Laboratory Investigation

Summary

Purpose of the study was to investigate the relationship between antioxidant enzyme expression and clinicopathological features in oligodendroglial tumors. The expression of antioxidant enzymes and related proteins (AOEs),␣manganese superoxide dismutase (MnSOD), thioredoxin (Trx), thioredoxin reductase (TrxR) and gammaglutamylcysteine synthetase catalytic and regulatory subunits (GLCL-C and GLCL-R), was studied in 85 oligodendroglial tumors. The material included 71 primary (43 grade II and 28 grade III) and 14 recurrent (6 grade II and 8 grade III) tumors. Fifty-seven cases were pure oligodendrogliomas and 28 were mixed oligoastrocytomas. Immunoreactivity for MnSOD was found in 89%, Trx in 29%, TrxR in 76%, GLCL-C in 70% and GLCL-R in 68% of cases. Increased Trx expression was associated with higher tumor grade, cell proliferation and apoptosis (P=0.006, P=0.001 and P=0.003, Mann–Whitney test). Pure oligodendrogliomas showed more intense staining than oligoastrocytomas, especially for MnSOD (P=0.002, Mann–Whitney test). In the total series Trx was associated with poor prognosis in univariate survival analysis (P=0.0343, log-rank test) and furthermore in Cox multivariate analysis (P=0.009) along with age (P=0.002). The results suggest that the expression of Trx has a correlation to patient outcome and that there may be some association between AOEs, like MnSOD and Trx, and clinicopathological features of oligodendrogliomas.

Keywords

gliomas manganese superoxide dismutase thioredoxin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

Eila Pohjola, Reija Randen and Salla Kolmihaara are warmly thanked for their assistance. This study was financially supported by Medical Research Fund of Tampere University Hospital, Pirkanmaa Cancer Society, Cancer Society of Finland and Cancer Society of southwestern Finland.

References:

  1. 1.
    Kleihues P, Cavanee WK, (eds) 2000 Pathology and Genetics. Tumours of the Nervous System, World Health Organization Classification of Tumours Lyon International Agency for Research on CancerGoogle Scholar
  2. 2.
    Reifenberger G, Louis DN, Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology J Neuropathol Exp Neurol 62 (2):111–126 2003PubMedGoogle Scholar
  3. 3.
    Fortin D, Cairncross GJ, Hammond RR, Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment Neurosurgery 45(6):1279–1291 1999PubMedCrossRefGoogle Scholar
  4. 4.
    Halliwell B, Reactive oxygen species in living systems: source, biochemistry, and role in human disease Am J Med 91(3C): 14S–22S 1991PubMedCrossRefGoogle Scholar
  5. 5.
    Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paakko P, Holmgren A, Kinnula VL, Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma Clin Cancer Res 7 (6):1750–1757 2001PubMedGoogle Scholar
  6. 6.
    Powis G, Montfort WR, Properties and biological activities of thioredoxins Annu Rev Biophys Biomol Struct 30:421–455, 2001PubMedCrossRefGoogle Scholar
  7. 7.
    Powis G, Kirkpatrick DL, Angulo M, Baker A: Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 111–112: 23–34, 1998Google Scholar
  8. 8.
    Powis G, Oblong JE, Gasdaska PY, Berggren M, Hill SR, Kirkpatrick DL: The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol Res 10–11 (6): 539–544, 1994Google Scholar
  9. 9.
    Kinnula V, Crapo J, Superoxide dismutases in the lung and human lung diseases Am J Respir Crit Care Med 167: 1600–1619 2003PubMedCrossRefGoogle Scholar
  10. 10.
    Church SL, Grant JW, Meese EU, Trent JM, Sublocalization of the gene encoding manganese superoxide dismutase (MnSOD/SOD2) to 6q25 by fluorescence in situ hybridization and somatic cell hybrid mapping Genomics 14 (3): 823–825 1992PubMedCrossRefGoogle Scholar
  11. 11.
    Paunu N, Sallinen SL, Karhu R, Miettinen H, Sallinen P, Kononen J, Laippala P, Simola KO, Helen P, Haapasalo H, Chromosome imbalances in familial gliomas detected by comparative genomic hybridization Gene Chromosome Canc 29 4:339–346 2000CrossRefGoogle Scholar
  12. 12.
    Marklund SL, Westman NG, Lundgren E, Roos G, Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues Can Res 42 5:1955–1961 1982Google Scholar
  13. 13.
    Li Y, Huang T-T, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ, Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase Nat Genet 11 4:376–381 1995PubMedCrossRefGoogle Scholar
  14. 14.
    Carlsson LM, Jonnson J, Edlund T, Marklund SL, Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia Proc Natl Acad Sci USA 92 14:6264–6268 1995PubMedCrossRefGoogle Scholar
  15. 15.
    Cobbs CS, Whisenhunt TR, Wesemann DR, Harkins LE, Van Meir EG, Samanta M, Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells Can Res 63 24:8670–8673 2003Google Scholar
  16. 16.
    Kinnula V, Pietarinen-Runtti P, Raivio K, Kahlos K, Pelin K, Mattson K, Linnainmaa K, Manganese superoxide dismutase in human pleural mesotheliomas cell lines Free Rad Biol Med 21 4:527–532 1996PubMedCrossRefGoogle Scholar
  17. 17.
    Kahlos K, Anttila S, Asikainen T, Kinnula K, Raivio KO, Mattson K, Linnainmaa K, Kinnula VL, Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma Am J Respir Cell Mol Biol 18 4:570–580 1998PubMedGoogle Scholar
  18. 18.
    Kahlos K, Paakko P, Kurttila E, Soini Y, Kinnula VL, Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma Br J Cancer 82 5:1022–1029 2000PubMedCrossRefGoogle Scholar
  19. 19.
    Kahlos K, Soini Y, Paakko P, Saily M, Linnainmaa K, Kinnula VL, Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma Int J Cancer 88 1:37–43 2000PubMedCrossRefGoogle Scholar
  20. 20.
    Haapasalo H, Kylaniemi M, Paunu N, Kinnula VL, Soini Y, Expression of antioxidant enzymes in astrocytic brain tumors Brain Pathol 13 2:155–164 2003PubMedCrossRefGoogle Scholar
  21. 21.
    Holmgren A, Björnstedt M, Thioredoxin and thioredoxin reductase Method Enzymol 252:199–208 1995CrossRefGoogle Scholar
  22. 22.
    Mustacich D, Powis G, Thioredoxin reductase Biochem J 346:1–8 2000PubMedCrossRefGoogle Scholar
  23. 23.
    Sun QA, Wu Y, Zappacosta F, Jeang KT, Lee BJ, Hatfield DL, Gladyshev VN, Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases J Biol Chem 274 35:24522–24530 1999PubMedCrossRefGoogle Scholar
  24. 24.
    Tew KD, Glutathione-associated enzymes in anticancer drug resistance Cancer Res 54(16):4313–4320 1994PubMedGoogle Scholar
  25. 25.
    Zhang K, Mack P, Wong KP, Glutathione-related mechanisms in cellular resistance to anticancer drugs Int J Oncol 12(4):871–882 1998PubMedGoogle Scholar
  26. 26.
    Dalton TP, Dieter MZ, Yang Y, Shertzer HG, Nebert DW, Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous Biochem Biophys Res Commun 279 2: 324 2000PubMedCrossRefGoogle Scholar
  27. 27.
    Järvinen K, Soini Y, Kahlos K, Kinnula VL, Overexpression of gamma-glutamylcysteine synthetase in human malignant mesothelioma Hum Pathol33(7):748–755 2002PubMedCrossRefGoogle Scholar
  28. 28.
    Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ, Prognostication of astrocytomas patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples J Pathol 174(4):275–282 1994PubMedCrossRefGoogle Scholar
  29. 29.
    Miettinen HE, Paunu N, Rantala I, Kalimo H, Paljärvi L, Helin H, Haapasalo H, Cell cycle regulators (p51, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique J Neurooncol 55(1):29–37 2001PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang Y, Zhao W, Zhang H, Domann FE, Oberley H, Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth Cancer Res62(4):1205–1212 2002PubMedGoogle Scholar
  31. 31.
    Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, Trent JM, Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells Proc Natl Acad Sci USA 90(7):3113–3117 1993PubMedCrossRefGoogle Scholar
  32. 32.
    Liang BC, Ross DA, Greenberg HS, Meltzer PS, Trent JM, Evidence of allelic imbalance of chromosome 6 in human astrocytomas Neurology 44:533–536 1994PubMedGoogle Scholar
  33. 33.
    Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G, Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival J Lab Clin Med 142(1):46–51 2003PubMedCrossRefGoogle Scholar
  34. 34.
    Hu J, Ma X, Lindner DJ, Karra S, Hofmann ER, Reddy SP, Kalvakolan DV, Modulation of p53 dependent gene expression and cell death through thioredoxin–thioredoxin reductase by Interferon-Retinoid combination Oncogene 20 31:4235–4248 2001PubMedCrossRefGoogle Scholar
  35. 35.
    Cairncross G, MacDonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, et al. Chemotherapy for anaplastic oligodendroglioma National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 12(10):2013–2021 1994PubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Järvelä Sally
    • 1
  • Bragge Helena
    • 2
  • Paunu Niina
    • 3
  • Järvelä Timo
    • 4
  • Paljärvi Leo
    • 1
    • 5
  • Kalimo Hannu
    • 6
  • Helén Pauli
    • 7
  • Kinnula Vuokko
    • 8
  • Soini Ylermi
    • 9
  • Haapasalo Hannu
    • 1
  1. 1.Department of PathologyTampere University HospitalTampereFinland
  2. 2.Department of OphthalmologyTampere University HospitalTampereFinland
  3. 3.Department of OncologyTampere University HospitalTampereFinland
  4. 4.Department of Orthopaedics and TraumatologyTampere City HospitalTampereFinland
  5. 5.Department of PathologyKuopio University HospitalKuopioFinland
  6. 6.Departments of PathologyTurku and Helsinki University HospitalsTurku and HelsinkiFinland
  7. 7.Department of NeurosurgeryTampere University HospitalTampereFinland
  8. 8.Department of Medicine, Division of Pulmonary MedicineHelsinki University HospitalHelsinkiFinland
  9. 9.Department of PathologyUniversity of OuluOuluFinland

Personalised recommendations